Emergence of ceftazidime-avibactam-resistant Klebsiella pneumoniae during treatment, Finland, December 2018.
Euro Surveill. 2019 05; 24(19)ES

Abstract

In December 2018, a ceftazidime-avibactam (CAZ-AVI)-resistant KPC-2-producing Klebsiella pneumoniae strain was isolated in Finland. CAZ-AVI resistance was observed 34 days after CAZ-AVI treatment in a trauma patient transferred from a hospital in Greece who had been colonised with blaKPC-2-producing K. pneumoniae ST39, and later developed a bloodstream infection. The CAZ-AVI-resistant strain contained a novel 15 amino acid insertion in the KPC-2 protein causing structural changes proximal to the KPC-2 active site.

Links

Publisher Full Text
ncbi.nlm.nih.gov
eurosurveillance.org
PMC Free PDF

Authors+Show Affiliations

Räisänen K
Department of Health Security, National Institute for Health and Welfare, Helsinki, Finland.
Koivula I
Kuopio University Hospital, Unit of Infections and Hospital hygiene, Kuopio University Hospital, Kuopio, Finland.
Ilmavirta H
Eastern Finland laboratory Centre, Kuopio, Finland.
Puranen S
Aalto University, Department of Computer Science, Espoo, Finland.
Kallonen T
Department of Biostatistics, University of Oslo, Oslo, Norway. Department of Health Security, National Institute for Health and Welfare, Helsinki, Finland.
Lyytikäinen O
Department of Health Security, National Institute for Health and Welfare, Helsinki, Finland.
Jalava J
Department of Health Security, National Institute for Health and Welfare, Helsinki, Finland.

MeSH

Anti-Bacterial AgentsAzabicyclo CompoundsBacterial ProteinsCeftazidimeDrug CombinationsDrug Resistance, BacterialHumansKlebsiella InfectionsKlebsiella pneumoniaeMicrobial Sensitivity TestsTreatment OutcomeTrimethoprim, Sulfamethoxazole Drug Combinationbeta-Lactamase Inhibitors

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

31088601